Novartis gets win for another Avidity muscular dystrophy AOC
Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.
Basketball great Shaq fronts Lilly sleep apnoea campaign
Eli Lilly has recruited basketball legend Shaquille O'Neal to promote a sleep apnoea awareness campaign and make the case for treatment with Zepbound.
Anthropic puts life sciences at heart of new AI model
Anthropic has released Claude Fable 5, trumpeting its R&D credentials, but has faced a backlash over "safeguards" built into the model.
SonoThera's $125m Series B heads recent biofinancings
Our latest roundup of financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.
Lilly wins new FDA approval for eczema drug Ebglyss
Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery